Clinical performance is complex and often involves multi-systemic burdens. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment programs for the treatment and management of anti-synthetic syndrome of the IVIG require individual development, typically including multidimensional management, including drug therapy, rehabilitation interventions, regular follow-up, etc. In recent years, with the development of therapeutically oriented, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immunodeficiency disorders that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of IVIG in the fight against synthetase syndrome. The platform serves the China International Medical Service System, a team of domestically authoritative experts in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.